The authors present their experience of treating anti-cancer drug extravasation by means of a composite surgical technique that consists of infiltration with physiological solution and hyaluronidase and subsequent manual aspiration of solutes alternated with profuse irrigation of the infiltrated area. In the immediate post-op we carry out a medical therapy that consists of calciparine and topical antibiotic and/or steroid creams. Since the year 2000 this technique has been used on 25 patients. We have had neither complications nor scars.

INTRODUCTION

In the last few years, due to an increase in the use of various chemotherapeutic protocols, we have seen a directly proportional increase in extravasation injuries. An “extravasation injury” is usually damage caused by accidental leakage of solutions from the vein to the surrounding tissue spaces. The administration of chemotherapeutic antiblastics involves problems of toxicity that we do not usually have when dealing with other drugs.

Chemotherapeutic antiblastics aim at the destruction of cells. This therapeutic objective is both difficult to evaluate and irreversible. Moreover, the treatment is not selective as regards neoplastic cells so that we can easily understand what damage it can cause to neighboring tissues.

Extravasation injuries are among the most dangerous toxic effects of chemotherapy and they should be avoided and prevented rather than treated. This is both because local damage is often serious and because there are no specific treatments.

Infiltration of the drug in the subcutaneous tissue can cause damage which can span from light erythema to serious necrosis. The symptoms of extravasation injuries which a patient can notice are burning, pain, or intense paraesthesia which are localised where the infiltration took place. Other symptoms include reddening, inflammation, swelling, and edema.

Medical literature abounds in works on this topic; nonetheless there is not a univocal protocol to treat extravasation injuries yet [1,2]. That is the reason why different treatments have been used—including topical hypothermia, infiltration of physiological solution, hyaluronidase, cortisone creams, antidotes, and even surgical excision of the ulcer [3–8].

It is worth stressing that, on the basis of different case reports, in oncological patients who are being submitted to chemotherapy the incidence of extravasation injuries varies between 0.5% and 22%. However, there is a constant increase of 1%–2.5% every year which perhaps is also due to an increase in the use of chemotherapy in several oncological protocols.
Local damage varies depending on the following parameters:

- Type of drug—vesiculating, exfoliating, irritating or neutral,
- Quantity of infused drug,
- Area of the infiltration.

Some factors can cause bigger damage; among them it is worth remembering high osmolarity treatments and treatments in which the drug can precipitate or closely bind to cellular structures like DNA, RNA, microtubules.

For the sake of convenience, in order to better devise treatment, antiblastic drugs are divided into four groups on the basis of their potential capacity to cause damage to tissues when extravasation injuries arise:

1. Vesiculating: these drugs can provoke serious cell damage or destroy tissues (necrosis). They cause bad and prolonged pains, fibrosis, and loss of mobility (Fig. 1).
2. Exfoliating: these are drugs that can cause cell damage and destruction of the skin tissue; redness and marked swelling are often immediately apparent, desquamation develops and progresses to ulcer formation.
3. Irritating and inflammatory: these drugs, when extravasated, can provoke pains, inflammation, flare reaction, including redness, either in the area where they are infused or along the vessel, or ulceration and rare destruction of the tissues.


As already mentioned, this distinction is made purely for convenience purposes. Hence we had better consider each episode of extravasation injury as significant and worth paying attention to, whatever the drug that provoked it is.

Nowadays, vesiculating antiblastics are the most dangerous and also the most used injectable substances (see Table I). Among them there is doxorubicin which together with other antraciclin drugs is surely one of the most feared vesiculating drugs because of its capacity to bind to adipose tissue and, above all, to combine itself

| TABLE I. Classification of Antiblastic Drugs on the Basis of the Potential Tissue Damage They can Cause |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Vesiculating: Group 1                                    | Exfoliating: Group 2                                      | Irritating and inflaming: Group 3                        | Neutral: Group 4                                          |
| Amsacrine                                                | Aclarubicin                                              | Carboplatin                                              | Asparaginase                                             |
| Carmustine                                                | Cisplatin                                                | Etoposide                                                | Bleomicine                                               |
| Dacarbazine                                               | Docetaxel                                                | Irinotecan                                                | Cladribine                                               |
| Dactinomicine                                             | Liposomal daunorubicin                                   | Teniposide                                                | Cyclophosphamide                                         |
| Daunorubicin                                              | Liposomal Doxorubicin                                    | Phosphate etoposide                                       | Cytarabine                                               |
| Doxorubicin                                               | Fluoruridine                                             | 5-Fluorouracil                                            | Edroclomab                                               |
| Epirubicin                                                | Mitozantrone                                             | Methotrexate                                              | Fludarabine                                              |
| Idarubicin                                                | Oxaliplatin                                              |                                                          | Gemcitabine                                              |
| Melphalan                                                 | Topotecan                                                |                                                          | Ifosfamide                                               |
| Mitomycin                                                 |                                                          |                                                          | Pentostatin                                              |
| Mustine                                                   |                                                          |                                                          | Rituximab                                                |
| Paclitaxel                                                |                                                          |                                                          | Thiotepa                                                 |
| Streptozocin                                              |                                                          |                                                          | Beta-interferon                                           |
| Treosulfan                                                |                                                          |                                                          | Aldesleukin (IL-2)                                        |
| Vinblastine                                               |                                                          |                                                          |                                                          |
| Vincristine                                               |                                                          |                                                          |                                                          |
| Vindesine                                                 |                                                          |                                                          |                                                          |
| Vinorelbine                                               |                                                          |                                                          |                                                          |
with the DNA in the complex DNA–topoisomerase II, to block the synthesis of both DNA and RNA and to provoke cell death. Other dangerous substances are vincristin, cisplatin, and vinblastin. All of them at first provoke severe local inflammation then, after a few days, tissue ulceration and necrosis.

This article is about our experience of the use of a conservative surgical protocol combined with a medical treatment which consists of dilution and aspiration of the extravasated solute by means of abundant irrigation of the infiltrated area. Moreover, we will group various aspects with the aim of finding the right protocol to follow when dealing with extravasation injuries caused by antiblastic drugs [9–13].

Our aim is to evaluate the advantages of this treatment as regards functional and scar outcomes and also the oncological patient’s quality of life.

SURGICAL TECHNIQUE

Our surgical protocol contemplates four stages:

1. Infiltration
2. First aspiration
3. Washout/irrigation
4. Second aspiration

First of all, this technique contemplates infiltration of saline solution in subcutaneous tissues where the extravasation injury is. This operation must be carried out as soon as possible after the accidental event has occurred.

The treatment starts by administering intradermic or subcutaneous local anaesthetic (Ropivacain 7.5%) and hyaluronidase (Jaluran<sub>®</sub> <600 UI). Obviously, the quantity to be injected is directly proportional to the area to treat and to tissue tension (Fig. 2). During this stage the aim is to dilute the extravasated drug in order to make aspiration easier. With the scalpel (Fig. 3), some small holes in the skin are created (8–10). Through them some subcutaneous tunnels are created to aspirate the liquid by means of lipoaspiration cannulas measuring 2 mm (Fig. 4). Of course, the noble underlying structures should always be respected (superficial vessels, nervous fascicles, tendons).

Then, through the skin holes, we carry out a second infiltration of saline solution which varies between 500 and 3,000 ml—depending on the area—and serves as an abundant irrigation (Fig. 5). This infiltration is followed by another aspiration.

The skin holes are never sutured (Fig. 6); they are just medicated with antibiotic cream and vaselined gauze. Soft, compressive bandage will then favor further liquid drainage by means of imbibition and capillarity.

When extravasations injuries take place in the back of the hand this must be treated with particular care—fingers are separated by means of gauze in order to avoid maceration. In the immediate post-op the anti-declivous position is advised. Finger mobilization is encouraged in order to favor drainage. In the post-op stage we administer low dose calciparine (0.3 U.I.) for 2–3 days and wide-spectrum antibiotics (cephazoline).

Post-op oedemas disappear after 24–40 hr and the skin holes heal in 4–8 days. We have seen that it is better to remove and dilute as much extravasated solute as possible, preferably within 36 hr.

We just carry out hyaluronidase infiltration on patients who come to us after 48 hr with oedemas or inflammation or a flush. By contrast, when no clear clinical signs are present, we do not carry out any treatment but we see the patient every day for the first week.
MATERIALS AND METHODS
Our case report is made-up of 25 oncological patients that—from January 2000 to date—came to us within 36 hr of the traumatic event. Fifteen of the patients are women, while 10 are men whose age ranges between 29 and 72 years (average age 58 years). Presumably, the quantity of extravasated liquid varied between 10 and 35 mm³.

The time gap which elapsed between the extravasation and its treatment varies between 100 min and 36 hr.

The most affected areas are the hand back, the wrist volar fold, the elbow fold, the anti-cubital fossa, the forearm, and the arm bicipital groove (this is because in the absence of Implantable Systems—port-a-cath—either the medial and lateral veins of the forearm—cephalic and basilic—or the veins on the back of the hand are cannulated).

The follow-up varies between 8 months and 4 years, 16 months on average. During the observation period we did not see infections, haematomas, excessive bleeding, skin paraesthesias, scar retractions, or other significant complications apart from very small hyperpigmented areas and one temporary oedema which in any case healed in a few weeks.

Patients who were treated within a few hours did not have any inflammation and healed faster. No patients had difficulty in moving their fingers or wrists. Functionality was preserved and we did not notice any skin ulcerations or damage to soft tissues (Fig. 7).

DISCUSSION AND CONCLUSIONS
Extravasations of antiblastic chemotherapeutic drugs are fortuitous and unpredictable events. Of course, there are various more or less invasive treatments to choose
from but they must be carefully considered in relation to each case. The possibility of developing effective anti-
dotes may help treat this pathology in future.

Sodium bicarbonate, dimethylsulfoxid (DMSO), and
glucocorticoids have been and are still used. They are
certainly useful but they cannot always be administered
and are not always effective.

By contrast, according to F. R. Heckler’s [10] and
J. J. Disa’s [7] studies, the hyaluronidase enzyme seems
to be very useful. It dissolves the binding of hyaluronic
acid in tissues and expands the intra-tissue space thus
creating a wider surface for dilution and for drug
aspiration.

We would like to stress that treatment should be started
as quickly as possible.

This technique is particularly useful for extravasations
of vesiculating and exfoliating antiblastics (see Table I)
and when the quantity of extravasated drug is equal or
above 10 cc.

When dealing with extravasations caused by che-
motherapeutic antiblastic vesiculating, exfoliating, and
irritating drugs we do not agree with the “wait and see”
protocol because of high risk of progressively worse
ulcerations and necrosis which often, apart from the skin,
affet the surrounding soft tissues provoking irreversible
damage.

Moreover, the administration of local anaesthetic does
not involve particular side effects in oncological patients.

Extravasation injuries should be considered as onco-
logical medical-surgical emergencies to be treated imme-
diately (within a few hours rather than days) if we want to
limit damage and prevent those severe and disfiguring
ulcerations which lack of treatment can provoke.

REFERENCES

1. Larson DL: What is the appropriate management of tissue extra-
2. Treatment of extravasation injury. The National Extravasation
Information Service. On URL: http://www.extravasation.org.uk
3. Lambert F, Couturaud B, Arnaud E, et al.: Extravasations
iatrogènes de solutes cytotoxique ou hyperosmolaires. Prise en
charge thérapeutique. Encycl Med Chir—Chirurgie plastique
reconstructive et esthétique, 1999:5:45–149.
4. Cichetti S, Jemec B, Gault DT: Two case reports of vinorelbine
extravasation: Management and review of the literature. Tumori,
5. Scuderi N, Onesti MG: Antitumor agents: Extravasation, manage-
extravasation injuries. The effectiveness of hyaluronidase in their
induced full thickness loss using hyaluronidase infiltration. Plast
8. Sommer NZ, Bayati S, Neumeister M, et al.: Dapsone for the
treatment of doxorubicin extravasation injury in the rat. Plast
9. Dorr RT: What is the appropriate management of tissue
extravasation by antitumor agents? (Discussion). Plast Reconstr
11. Vandeweyer E, Heymans O, Deraemaeker R: Extravasation
injuries and emergency suction as treatment. Plast Reconstr Surg
12. Casanova D, Bardot J, Magalon G: Emergency treatment of
accidental infusion leakage in the newborn: Report of 14 cases.
13. Burd DAR, Santis G, Milward TM: Severe Extravasation injury:

COMMENTARY
Extravasation injury is a well-known adverse event
associated with intravenous chemotherapy administration
and occurs when drugs escape from the veins, catheters or
ports into subcutaneous tissues. The systematic use of
central access catheters and ports has drastically reduc-
ed the incidence of these complications, although they
still occur apparently at the rate of about 0.1%–6% in
patients receiving systemic chemotherapy. The local re-
actions are often distinguished into irritant and vesicant
reactions. The irritant-type are self-limited phlebitis and
erythematous reaction along the vein or at the site of
administration. The reaction by vesicants is often de-
scribed as chemical cellulitis, which initially presents in
a similar way to irritation but may worsen to result in
tissue necrosis. A large number of non-surgical treat-
ments have been attempted such as cold application and
elevation of the affected area with limited success, as well
as local injection of steroids, sodium bicarbonate, sodium
thiosulfate, hyaluronidase, and β-adrenergic agonists
and antagonists. Local application of DMSO has been
tried with some evidence that DMSO protected from
ulceration.

Systemic Dexrazoxane, an agent cardio-protective
from the effects of anthracycline has been found to

DOI 10.1002/jso.20252
Published online in Wiley InterScience (www.interscience.wiley.com).

© 2005 Wiley-Liss, Inc.